SCHEMBL1900651

SCHEMBL1900651

CCCCCNC(=O)c1ccc(OC2CCN(Cc3ccccc3)CC2)nn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
NPC1 O15118 1/20 0.47
LMNA P02545 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PRKAB2 O43741 1/20 0.46
PRKAG1 P54619 1/20 0.46
PRKAA2 P54646 1/20 0.46
PRKAA1 Q13131 1/20 0.46
PRKAG3 Q9UGI9 1/20 0.46
PRKAG2 Q9UGJ0 1/20 0.46
PRKAB1 Q9Y478 1/20 0.46
ABL1 P00519 1/20 0.46
RIN1 Q13671 1/20 0.46
ACHE P22303 2/20 0.44
SLC5A7 Q9GZV3 1/20 0.44
BCHE P06276 1/20 0.44
ACKR3 P25106 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1905776 0.82 ENPP2 (0.59) MAOAMAOBSMN1; SMN2PRKAB2PRKAG1
SCHEMBL1907708 0.81 OPRK1 (0.51) SMN1; SMN2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL9014112 0.77 OPRK1 (0.53) NPC1LMNARAB9ASMN1; SMN2L3MBTL1
SCHEMBL4464631 0.74 BCHE (0.65) NPC1LMNARAB9ASMN1; SMN2L3MBTL1
SCHEMBL11393297 0.72 NPC1 (0.56) NPC1LMNARAB9ASMN1; SMN2L3MBTL1
SCHEMBL8480700 0.72 BCHE (0.55) NPC1LMNARAB9ASMN1; SMN2L3MBTL1
SCHEMBL8480272 0.69 BCHE (0.63) MAOBACHEBCHE
SCHEMBL8717826 0.69 BCHE (0.60) LMNASMN1; SMN2ACHEBCHE
Hydrochloric Acid SCHEMBL9013903 0.69 SMN1; SMN2 (0.58) MAOAMAOBNPC1LMNARAB9A
SCHEMBL8534498 0.69 DRD4 (0.71) ABL1RIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2316458-A1 Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase Xenon Pharmaceuticals Inc. (CA) 2011-05-04 EP claimed
US-7829712-B2 Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase XENON PHARMACEUTICALS INC. (CA) 2010-11-09 US claimed
US-20080207587-A1 Pyridazine Derivatives for Inhibiting Human Stearoyl-Coa-Desaturase XENON PHARMACEUTICALS INC. (CA) 2008-08-28 US claimed
EP-1814551-A2 PYRIDAZINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE XENON PHARMACEUTICALS INC. (CA) 2007-08-08 EP claimed
WO-2006034341-A2 PYRIDAZINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE XENON PHARMACEUTICALS INC. (CA) 2006-03-30 WO claimed
EP-2316458-A1 Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase Xenon Pharmaceuticals Inc. (CA) 2011-05-04 EP disclosed
US-7829712-B2 Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase XENON PHARMACEUTICALS INC. (CA) 2010-11-09 US disclosed
US-20080207587-A1 Pyridazine Derivatives for Inhibiting Human Stearoyl-Coa-Desaturase XENON PHARMACEUTICALS INC. (CA) 2008-08-28 US disclosed
EP-1814551-A2 PYRIDAZINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE XENON PHARMACEUTICALS INC. (CA) 2007-08-08 EP disclosed
WO-2006034341-A2 PYRIDAZINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE XENON PHARMACEUTICALS INC. (CA) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207587-A1 Pyridazine Derivatives for Inhibiting Human Stearoyl-Coa-Desaturase SCD, SCD5, FADS2 MAOA 895/4885MAOB 811/4885NPC1 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.